The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Bob Duggan & Maky Zanganeh, Summit Therapeutics co-CEOs, join 'Fast Money' to talk its lung cancer drug and continuing ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $14 ...

Those following along with Summit Therapeutics Inc. (NASDAQ:SMMT) will no doubt be intrigued by the recent purchase of shares by Robert Duggan, Co-CEO & Executive Chairman of the company, who spent a ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...

Akeso and Summit Therapeutics' ivonescimab showed strong efficacy against Merck's Keytruda in a phase 3 trial in China. The ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, will present its ONCO Prime ...